At the request of the U.S. Food and Drug Administration (FDA), the National Academies of Sciences, Engineering, and Medicine appointed a committee of experts to prepare a report that examines the state of the science in pain management, characterizes the epidemiology of the opioid epidemic, and identifies actions that the FDA and other organizations can take to respond to this crisis, including the development of a formal model for incorporating individual and societal considerations into FDA’s risk-benefit framework for opioid approval and monitoring.
Members of the committee presented the findings and recommendations from the report during a public release webinar on Thursday, July 13. A recording of the webinar is available here.
FDA Commissioner Dr. Gottlieb comments delivered before the FDA meeting on Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Post Market Setting: A Scientific Discussion of Present and Future Capabilities on July 10, 2017
The ONDCP has issued a notice to advise the public that the Commission is rescheduling the teleconference of the President’s Commission on Combating Drug Addiction and the Opioid Crisis that was previously scheduled for Monday, July 17. The teleconference will be held on Monday, July 3, at 4 pm EST. The public may call 800.260.0718 and use access code 426289 to listen. The purpose of the meeting is to review a draft interim report that will be posted on ONDCP’s Commission website listed below before the teleconference. Please call five minutes before the start time.
The Department of Health & Human Services Study: Opioids in Medicare Part D: Concerns about Extreme Use and Questionable Prescribing
This data brief is part of a larger strategy by the Office of the Inspector General to fight the opioid crisis and address one of its top priority outcomes-to protect beneficiaries from prescription drug abuse. It provides baseline data on the extent to which beneficiaries receive extreme amounts of opioids and appear to be "doctor shopping." It also identifies prescribers who have questionable opioid prescribing patterns
On Thursday, July 13, the U.S. Justice Department and Attorney General Jeff Sessions announced a takedown on fraudulent opioid treatment programs, charging 412 people accused of defrauding the government of $1.3 billion, and barring almost nearly 300 providers from federal healthcare programs. For more information, watch Sessions' press conference.